Genes predict GLP‑1 results

Glucagon-like peptide 1 drugs copy a gut hormone your body releases after you eat, and that signal slows stomach emptying and turns down appetite. Semaglutide and tirzepatide use that pathway, which is why people often feel full sooner and eat less. (nature.com) The strange part is how uneven the results are. In 23andMe’s data, some people lost less than 5% of their body weight on these drugs, while others lost more than 20%, and nausea and vomiting were just as uneven. (23andme.com) A gene is a set of instructions for building a protein, and a variant is a one-letter edit in that instruction manual. If the drug is a key, a variant can slightly reshape the lock it fits into. (nature.com) The lock for these medicines is a protein called the glucagon-like peptide 1 receptor. The new Nature paper found that a missense variant in the GLP1R gene, which changes the receptor’s protein sequence, was linked to stronger weight-loss response. (nature.com) The study looked at 27,885 people who reported using glucagon-like peptide 1 medicines, making it one of the biggest attempts yet to connect DNA to real-world weight-loss drug results. The researchers ran a genome-wide association study, which is a scan across the genome to see which variants show up more often in people with a certain outcome. (nature.com) For weight loss, each copy of the key GLP1R variant was tied to an extra 0.76 kilograms, or about 1.7 pounds, of loss. That is a modest difference next to a median loss of about 25 pounds, but it is large enough to show that the drug target itself helps explain who responds better. (nature.com) (bloomberg.com) The side-effect signal pointed to two genes, not one. Variants in GLP1R and in GIPR, the gene for the gastric inhibitory polypeptide receptor, were linked to nausea or vomiting after treatment. (nature.com) That second gene matters because tirzepatide hits two locks at once: the glucagon-like peptide 1 receptor and the gastric inhibitory polypeptide receptor. In this study, the GIPR side-effect association showed up only in tirzepatide users, not in semaglutide users. (nature.com) (23andme.com) The practical idea is not that one gene will decide your prescription by itself. The researchers combined these variants with clinical and demographic factors in a model that could sort people by both likely weight-loss benefit and likely stomach side-effect risk. (nature.com) (23andme.com) That points toward a future where two patients with the same starting weight might not get the same drug or the same dose. One could be steered toward a medicine with a better odds of weight loss, while another could avoid a drug more likely to trigger nausea and quit treatment early. (nature.com) 23andMe said it has already turned the findings into a report for members of its Total Health service, but the bigger test is whether doctors and health systems can prove that genetics-guided prescribing improves outcomes in routine care. This paper shows the first direct genetic evidence in a very large cohort; it does not yet make genetic testing a standard rule before starting these drugs. (23andme.com) (nature.com)